Skip to content
TheChatArchiveThe Chat Archive
o1-preview-2024-09-12· OpenAIAi2 WildChat-4.8M (AI2)

Please rewrite and optimize this data extraction form: Stem Cell Transplant Data…

  1. User

    Please rewrite and optimize this data extraction form: Stem Cell Transplant Data Extraction Form

    1. Patient Information Variable Value Units (if applicable) Patient ID National Code Date of Birth (Age at transplant) years Gender Height cm Weight kg BMI kg/m² Race/Ethnicity
    2. Disease and Transplant Details Variable Value Date (if applicable) Primary Diagnosis Date of Diagnosis Disease Status at Transplant Type of Transplant (Autologous/Allogeneic) Date of Transplant Stem Cell Source HLA Matching (if allogeneic) out of 10 Donor Relationship (if allogeneic) Conditioning Regimen Graft Manipulation (Yes/No, specify)
    3. Pre-Transplant Assessment 3.1 Hematological Parameters Parameter At Diagnosis Pre-Transplant Units WBC count x10⁹/L Hemoglobin g/dL Neutrophil count x10⁹/L Lymphocyte count x10⁹/L Monocyte count x10⁹/L Platelet count x10⁹/L

    3.2 Biochemical Parameters Parameter Value Reference Range ALT U/L AST U/L BUN mg/dL Creatinine mg/dL Total Protein g/dL Albumin g/dL Calcium mg/dL Phosphorus mg/dL Ferritin ng/mL PTH pg/mL HDL Cholesterol mg/dL LDL Cholesterol mg/dL Triglycerides mg/dL Total Cholesterol mg/dL 3.3 Infectious Disease Markers Test Result (Positive/Negative) Date Titer/Value (if applicable) CMV IgG CMV IgM HSV IgG VZV IgG VZV IgM EBV IgG EBV IgM HBs Ab HBs IgM HBc Ab HBe Ab H. pylori IgG H. pylori IgA Toxoplasma IgG HIV antibody PPD test 4. Donor Information (for allogeneic transplants) Parameter Value Units WBC count x10⁹/L Hemoglobin g/dL Neutrophil count x10⁹/L Lymphocyte count x10⁹/L Monocyte count x10⁹/L Platelet count x10⁹/L Stem cell dose (MNC or CD34+) 5. Early Complications due to Transplant Complication Onset Date Severity Treatment Infections Acute GvHD (grade) Bronchiolitis Other (specify) 6. Pre-existing Conditions and Lifestyle Factors Factor Details Comorbidities Smoking Status 7. Prior Treatments Treatment Start Date End Date Response 1. 2. 3. 8. Long-term Follow-up and Survival Analysis (5-year period) 8.1 Overall Survival (OS) Parameter Value Date (if applicable) Survival Status at 5 years (Alive/Dead) Date of Death (if applicable) Cause of Death (if applicable) Time to Death (days from transplant) 8.2 Progression-Free Survival (PFS) Parameter Value Date (if applicable) Disease Status at 5 years (Progression/No Progression) Date of Progression (if applicable) Time to Progression (days from transplant) 8.3 Follow-up Assessments Parameter 30 days 100 days 6 months 1 year 5 years Disease status Chimerism (%) Key complications ECOG Performance Status Graft function 8.4 Late Effects and Long-term Complications Complication Onset Date Severity Treatment Resolved (Y/N) Chronic GvHD Secondary malignancies Endocrine dysfunction Cardiovascular complications Pulmonary complications Bone/joint complications Other (specify) 8.5 Subsequent Treatments Treatment Start Date End Date Reason Response 1. 2. 3. 4.

  2. Assistant

    Optimized Stem Cell Transplant Data Extraction Form


    Section 1: Patient Information

    VariableValueUnits
    Patient ID
    National Code
    Date of BirthYYYY-MM-DD
    Age at TransplantYears
    GenderM/F/Other
    Race/Ethnicity
    Heightcm
    Weightkg
    BMIkg/m²

    Section 2: Disease and Transplant Details

    VariableValueDate (if applicable)Units
    Primary Diagnosis
    Date of DiagnosisYYYY-MM-DD
    Disease Status at Transplant
    Type of TransplantAutologous / Allogeneic
    Date of TransplantYYYY-MM-DD
    Stem Cell Source
    Conditioning Regimen
    Graft ManipulationYes / No (If Yes, specify)

    If Allogeneic Transplant:

    VariableValueUnits
    HLA MatchingMatches out of 10
    Donor Relationship

    Section 3: Pre-Transplant Assessment

    3.1 Hematological Parameters

    ParameterAt DiagnosisPre-TransplantUnits
    WBC Count×10⁹/L
    Hemoglobing/dL
    Neutrophil Count×10⁹/L
    Lymphocyte Count×10⁹/L
    Monocyte Count×10⁹/L
    Platelet Count×10⁹/L

    3.2 Biochemical Parameters

    ParameterValueReference RangeUnits
    ALTU/L
    ASTU/L
    BUNmg/dL
    Creatininemg/dL
    Total Proteing/dL
    Albuming/dL
    Calciummg/dL
    Phosphorusmg/dL
    Ferritinng/mL
    PTHpg/mL
    HDL Cholesterolmg/dL
    LDL Cholesterolmg/dL
    Triglyceridesmg/dL
    Total Cholesterolmg/dL

    3.3 Infectious Disease Markers

    TestResult (Positive/Negative)Date (YYYY-MM-DD)Titer/Value (if applicable)
    CMV IgG
    CMV IgM
    HSV IgG
    VZV IgG
    VZV IgM
    EBV IgG
    EBV IgM
    HBs Ab
    HBs IgM
    HBc Ab
    HBe Ab
    H. pylori IgG
    H. pylori IgA
    Toxoplasma IgG
    HIV Antibody
    PPD Test

    Section 4: Donor Information (Allogeneic Transplants Only)

    ParameterValueUnits
    WBC Count×10⁹/L
    Hemoglobing/dL
    Neutrophil Count×10⁹/L
    Lymphocyte Count×10⁹/L
    Monocyte Count×10⁹/L
    Platelet Count×10⁹/L
    Stem Cell DoseSpecify (MNC or CD34+)

    Section 5: Early Complications Post-Transplant

    ComplicationOnset Date (YYYY-MM-DD)Severity (Grade)Treatment Provided
    Infections
    Acute GvHDGrade I–IV
    Bronchiolitis
    Other (Specify)

    Section 6: Pre-Existing Conditions and Lifestyle Factors

    FactorDetails
    Comorbidities(List any pre-existing conditions)
    Smoking StatusNever / Former / Current
    Alcohol UseNever / Occasional / Regular
    Other Factors(Specify)

    Section 7: Prior Treatments

    TreatmentStart Date (YYYY-MM-DD)End Date (YYYY-MM-DD)Response (CR/PR/SD/PD)
    1.
    2.
    3.

    Abbreviations:

    • CR: Complete Response
    • PR: Partial Response
    • SD: Stable Disease
    • PD: Progressive Disease

    Section 8: Long-Term Follow-Up and Survival Analysis (Up to 5 Years)

    8.1 Overall Survival (OS)

    ParameterValueDate (YYYY-MM-DD)
    Survival Status at 5 YearsAlive / Deceased
    Date of Death
    Cause of Death(Specify)
    Time to DeathDays from Transplant

    8.2 Progression-Free Survival (PFS)

    ParameterValueDate (YYYY-MM-DD)
    Disease Status at 5 YearsProgression / No Progression
    Date of Progression
    Time to ProgressionDays from Transplant

    8.3 Follow-Up Assessments

    Record at Each Time Point

    Parameter30 Days100 Days6 Months1 Year5 Years
    Disease Status
    Chimerism (%)
    Key Complications
    ECOG Performance Status
    Graft Function

    8.4 Late Effects and Long-Term Complications

    ComplicationOnset Date (YYYY-MM-DD)Severity (Grade)Treatment ProvidedResolved (Y/N)
    Chronic GvHD
    Secondary Malignancies
    Endocrine Dysfunction
    Cardiovascular Issues
    Pulmonary Complications
    Bone/Joint Problems
    Other (Specify)

    8.5 Subsequent Treatments

    TreatmentStart Date (YYYY-MM-DD)End Date (YYYY-MM-DD)Reason for TreatmentResponse (CR/PR/SD/PD)
    1.
    2.
    3.
    4.

    Additional Notes

    • Data Entry Instructions:

      • Use YYYY-MM-DD format for all dates.
      • Ensure all numeric values include units.
      • For any unavailable data, mark as N/A.
      • Use official grading scales (e.g., CTCAE) for severity.
      • Maintain patient confidentiality at all times.
    • Abbreviations:

      • WBC: White Blood Cell
      • GvHD: Graft-versus-Host Disease
      • ECOG: Eastern Cooperative Oncology Group
      • MNC: Mononuclear Cells
      • CD34+: Cluster of Differentiation 34 Positive Cells
      • ALT: Alanine Aminotransferase
      • AST: Aspartate Aminotransferase
      • BUN: Blood Urea Nitrogen
      • PTH: Parathyroid Hormone
    • Performance Status Scale:

      • ECOG 0: Fully active
      • ECOG 1: Restricted in physically strenuous activity
      • ECOG 2: Ambulatory, capable of all self-care
      • ECOG 3: Limited self-care
      • ECOG 4: Completely disabled

    Instructions for Data Collectors

    • Accuracy: Double-check all entries for accuracy and completeness.
    • Consistency: Use consistent units and terminologies throughout the form.
    • Clarifications: Refer to clinical records or consult with healthcare providers if any information is unclear.
    • Updates: Keep records updated with the latest follow-up information.
    • Confidentiality: Handle all patient data in compliance with HIPAA and institutional guidelines.

    By optimizing the structure and clarity of this form, data collection becomes more efficient and reliable, facilitating better patient care and research outcomes.